

Judith Greer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9307616/publications.pdf>

Version: 2024-02-01

88
papers

4,395
citations

101543

36
h-index

106344

65
g-index

89
all docs

89
docs citations

89
times ranked

6057
citing authors

#	ARTICLE	IF	CITATIONS
1	Sexual Dimorphism in the Immune System. , 2020, , 419-428.		2
2	Reduced I κ B- $\hat{\pm}$ Protein Levels in Peripheral Blood Cells of Patients with Multiple Sclerosisâ€”A Possible Cause of Constitutive NF- $\hat{\rho}$ B Activation. Journal of Clinical Medicine, 2020, 9, 2534.	2.4	2
3	Correlation Between Anti-Myelin Proteolipid Protein (PLP) Antibodies and Disease Severity in Multiple Sclerosis Patients With PLP Response-Permissive HLA Types. Frontiers in Immunology, 2020, 11, 1891.	4.8	14
4	Is there a role for antibodies targeting muscarinic acetylcholine receptors in the pathogenesis of schizophrenia?. Australian and New Zealand Journal of Psychiatry, 2019, 53, 1059-1069.	2.3	7
5	Increased constitutive activation of NF- $\hat{\rho}$ B p65 (RelA) in peripheral blood cells of patients with progressive multiple sclerosis. Journal of Neuroimmunology, 2018, 320, 111-116.	2.3	13
6	PLP1 Mutations in Patients with Multiple Sclerosis: Identification of a New Mutation and Potential Pathogenicity of the Mutations. Journal of Clinical Medicine, 2018, 7, 342.	2.4	23
7	Predicting the effects of potentially therapeutic modified peptides on polyclonal T cell populations in a mouse model of multiple sclerosis. Journal of Neuroimmunology, 2017, 307, 18-26.	2.3	1
8	Novel Therapeutics for Multiple Sclerosis Designed by Parasitic Worms. International Journal of Molecular Sciences, 2017, 18, 2141.	4.1	17
9	Reactivity to Novel Autoantigens in Patients with Coexisting Central Nervous System Demyelinating Disease and Autoimmune Thyroid Disease. Frontiers in Immunology, 2017, 8, 514.	4.8	8
10	A parasite-derived 68-mer peptide ameliorates autoimmune disease in murine models of Type 1 diabetes and multiple sclerosis. Scientific Reports, 2016, 6, 37789.	3.3	34
11	Interleukin 6 promoter 174 G/C polymorphisms in acute ischemic stroke: G allele is protective but not associated with IL-6 levels or stroke outcome. Journal of Neuroimmunology, 2016, 293, 22-27.	2.3	8
12	Autoantibodies and their potential roles in diseases of the nervous system. Clinical and Experimental Neuroimmunology, 2015, 6, 370-386.	1.0	7
13	Circulating brain derived neurotrophic factor (BDNF) and frequency of BDNF positive T cells in peripheral blood in human ischemic stroke: Effect on outcome. Journal of Neuroimmunology, 2015, 286, 42-47.	2.3	47
14	Taming the TCR: Antigen-Specific Immunotherapeutic Agents for Autoimmune Diseases. International Reviews of Immunology, 2015, 34, 460-485.	3.3	8
15	Characterization of a new rat model for chronic inflammatory demyelinating polyneuropathies. Journal of Neuroimmunology, 2015, 278, 1-10.	2.3	15
16	Correlation of Adrenomedullin gene expression in peripheral blood leukocytes with severity of ischemic stroke. International Journal of Neuroscience, 2014, 124, 271-280.	1.6	10
17	Increased expression of the hypoxiaâ€”related genes in peripheral blood leukocytes of human subjects with acute ischemic stroke. Clinical and Experimental Neuroimmunology, 2014, 5, 216-226.	1.0	2
18	The Role of HLA in MS Susceptibility and Phenotype. Current Topics in Behavioral Neurosciences, 2014, 26, 1-27.	1.7	11

#	ARTICLE	IF	CITATIONS
19	Thiopalmitylation of Altered Peptide Ligands Enhances Their Protective Effects in an Animal Model of Multiple Sclerosis. <i>Journal of Immunology</i> , 2014, 192, 2244-2251.	0.8	5
20	Sexual Dimorphism in the Immune System. , 2014, , 319-328.		3
21	Characterization of genetic variants in the NFKBIA promoter region in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2014, 275, 53-54.	2.3	0
22	PLP1 mutations in patients with multiple sclerosis: Identification of a new mutation and analysis of in vitro effects of PLP1 mutations. <i>Journal of Neuroimmunology</i> , 2014, 275, 100.	2.3	0
23	Quantitative Proteome Profiling of CNS-Infiltrating Autoreactive CD4 ⁺ Cells Reveals Selective Changes during Experimental Autoimmune Encephalomyelitis. <i>Journal of Proteome Research</i> , 2014, 13, 3655-3670.	3.7	10
24	Elevated levels of autoantibodies targeting the M1 muscarinic acetylcholine receptor and neurofilament medium in sera from subgroups of patients with schizophrenia. <i>Journal of Neuroimmunology</i> , 2014, 269, 68-75.	2.3	19
25	Female reproductive issues in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 392-402.	3.0	51
26	Autoimmune T-Cell Reactivity to Myelin Proteolipids and Glycolipids in Multiple Sclerosis. <i>Multiple Sclerosis International</i> , 2013, 2013, 1-16.	0.8	24
27	Interleukin-6 Gene Promoter-572 C Allele May Play a Role in Rate of Disease Progression in Multiple Sclerosis. <i>International Journal of Molecular Sciences</i> , 2012, 13, 13667-13679.	4.1	17
28	Closing the case of APOE in multiple sclerosis: no association with disease risk in over 29,000 subjects: Figure 1. <i>Journal of Medical Genetics</i> , 2012, 49, 558-562.	3.2	31
29	Gene Expression in the Spinal Cord in Female Lewis Rats with Experimental Autoimmune Encephalomyelitis Induced with Myelin Basic Protein. <i>PLoS ONE</i> , 2012, 7, e48555.	2.5	12
30	The role of epigenetic mechanisms and processes in autoimmune disorders. <i>Biologics: Targets and Therapy</i> , 2012, 6, 307.	3.2	51
31	Frequency and function of regulatory T cells after ischaemic stroke in humans. <i>Journal of Neuroimmunology</i> , 2012, 243, 89-94.	2.3	70
32	Prolonged elevation of cytokine levels after human acute ischaemic stroke with evidence of individual variability. <i>Journal of Neuroimmunology</i> , 2012, 246, 78-84.	2.3	22
33	Levels of phosphorylated axonal neurofilament subunit H (pNfH) are increased in acute ischemic stroke. <i>Journal of the Neurological Sciences</i> , 2011, 304, 117-121.	0.6	58
34	Modeling the cumulative genetic risk for multiple sclerosis from genome-wide association data. <i>Genome Medicine</i> , 2011, 3, 3.	8.2	63
35	Role of gender in multiple sclerosis: Clinical effects and potential molecular mechanisms. <i>Journal of Neuroimmunology</i> , 2011, 234, 7-18.	2.3	119
36	Comparing genotyping algorithms for Illumina's Infinium whole-genome SNP BeadChips. <i>BMC Bioinformatics</i> , 2011, 12, 68.	2.6	38

#	ARTICLE	IF	CITATIONS
37	The effect of ageing on human lymphocyte subsets: comparison of males and females. <i>Immunity and Ageing</i> , 2010, 7, 4.	4.2	133
38	Saliva-Derived DNA Performs Well in Large-Scale, High-Density Single-Nucleotide Polymorphism Microarray Studies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 794-798.	2.5	52
39	Investigation of the [A]8 and C1236T genetic variations within the human toll-like receptor 3 gene for association with multiple sclerosis. <i>Neurological Research</i> , 2010, 32, 438-441.	1.3	4
40	Prominent brainstem and cerebellar involvement in multiple sclerosis with psoriasis. <i>Multiple Sclerosis Journal</i> , 2009, 15, 763-766.	3.0	10
41	Sexual Dimorphism in Autoimmune Disease. <i>Current Molecular Medicine</i> , 2009, 9, 1058-1079.	1.3	144
42	Immune activation in the peripheral blood of patients with acute ischemic stroke. <i>Journal of Neuroimmunology</i> , 2009, 206, 112-117.	2.3	98
43	An investigation of the C77G and C772T variations within the human protein tyrosine phosphatase receptor type C gene for association with multiple sclerosis in an Australian population. <i>Brain Research</i> , 2009, 1255, 148-152.	2.2	12
44	Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. <i>Nature Genetics</i> , 2009, 41, 824-828.	21.4	501
45	HLA-DRB1 associations with disease susceptibility and clinical course in Australians with multiple sclerosis. <i>Tissue Antigens</i> , 2009, 74, 17-21.	1.0	40
46	CTLA-4 single-nucleotide polymorphisms in a Caucasian population with schizophrenia. <i>Brain, Behavior, and Immunity</i> , 2009, 23, 347-350.	4.1	16
47	Study of leukemia inhibitory factor polymorphism within an Australian multiple sclerosis population. <i>Journal of the Neurological Sciences</i> , 2009, 280, 62-64.	0.6	0
48	Myelin proteolipid protein: An effective autoantigen and target of autoimmunity in multiple sclerosis. <i>Journal of Autoimmunity</i> , 2008, 31, 281-287.	6.5	40
49	NF- κ B, a Potential Therapeutic Target for the Treatment of Multiple Sclerosis. <i>CNS and Neurological Disorders - Drug Targets</i> , 2008, 7, 536-557.	1.4	86
50	Correlation of Blood T Cell and Antibody Reactivity to Myelin Proteins with HLA Type and Lesion Localization in Multiple Sclerosis. <i>Journal of Immunology</i> , 2008, 180, 6402-6410.	0.8	39
51	Route of Uptake of Palmitoylated Encephalitogenic Peptides of Myelin Proteolipid Protein by Antigen-Presenting Cells: Importance of the Type of Bond between Lipid Chain and Peptide and Relevance to Autoimmunity. <i>Journal of Immunology</i> , 2008, 180, 1398-1404.	0.8	25
52	Immunology of multiple sclerosis. <i>Current Allergy and Asthma Reports</i> , 2007, 7, 285-292.	5.3	79
53	Studies of HLA associations in male and female patients with Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). <i>Journal of Neuroimmunology</i> , 2006, 180, 172-177.	2.3	42
54	Immune dysregulation and self-reactivity in schizophrenia: Do some cases of schizophrenia have an autoimmune basis?. <i>Immunology and Cell Biology</i> , 2005, 83, 9-17.	2.3	127

#	ARTICLE	IF	CITATIONS
55	Bloodâ€“brain barrier disruption and lesion localisation in experimental autoimmune encephalomyelitis with predominant cerebellar and brainstem involvement. <i>Journal of Neuroimmunology</i> , 2005, 160, 162-169.	2.3	59
56	The presence of glutamic acid at positions 71 or 74 in pocket 4 of the HLA-DRÂ1 chain is associated with the clinical course of multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, 656-662.	1.9	28
57	Increased circulating T cell reactivity to GM1 ganglioside in patients with Guillainâ€“BarrÃ© syndrome. <i>Journal of Clinical Neuroscience</i> , 2005, 12, 409-415.	1.5	27
58	Chemokines and Chemokine Receptors: Potential Therapeutic Targets in Multiple Sclerosis. <i>Inflammation and Allergy: Drug Targets</i> , 2004, 3, 279-290.	3.1	32
59	Effect of gender on T-cell proliferative responses to myelin proteolipid protein antigens in patients with multiple sclerosis and controls. <i>Journal of Autoimmunity</i> , 2004, 22, 345-352.	6.5	31
60	Solid-phase synthesis of a biotin-labelled thiopalmitoylated myelin proteolipid protein epitope and application in the study of uptake of antigen by macrophages. <i>International Journal of Peptide Research and Therapeutics</i> , 2003, 10, 581-587.	1.9	3
61	Solid-phase synthesis of a biotin-labelled thiopalmitoylated myelin proteolipid protein epitope and application in the study of uptake of antigen by macrophages. <i>International Journal of Peptide Research and Therapeutics</i> , 2003, 10, 581-588.	0.1	8
62	Identification of the di-pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti-tumour agents. <i>British Journal of Pharmacology</i> , 2003, 138, 819-830.	5.4	94
63	Increased circulating T cell reactivity to GM3 and GQ1b gangliosides in primary progressive multiple sclerosis. <i>Journal of Clinical Neuroscience</i> , 2003, 10, 63-66.	1.5	57
64	Erythroid differentiation and protoporphyrin IX down-regulate frataxin expression in Friend cells: characterization of frataxin expression compared to molecules involved in iron metabolism and hemoglobinization. <i>Blood</i> , 2002, 99, 3813-3822.	1.4	69
65	Myelin proteolipid proteinâ€“the first 50 years. <i>International Journal of Biochemistry and Cell Biology</i> , 2002, 34, 211-215.	2.8	83
66	Thiopalmitoylation of Myelin Proteolipid Protein Epitopes Enhances Immunogenicity and Encephalitogenicity. <i>Journal of Immunology</i> , 2001, 166, 6907-6913.	0.8	29
67	A neuropathological analysis of experimental autoimmune encephalomyelitis with predominant brain stem and cerebellar involvement and differences between active and passive induction. <i>Acta Neuropathologica</i> , 2000, 100, 174-182.	7.7	67
68	Surges of Increased T Cell Reactivity to an Encephalitogenic Region of Myelin Proteolipid Protein Occur More Often in Patients with Multiple Sclerosis Than in Healthy Subjects. <i>Journal of Immunology</i> , 2000, 165, 5322-5331.	0.8	62
69	Early pregnancy factor suppresses experimental autoimmune encephalomyelitis induced in Lewis rats with myelin basic protein and in SJL/J mice with myelin proteolipid protein peptide 139-151. <i>Journal of the Neurological Sciences</i> , 2000, 182, 5-15.	0.6	33
70	Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis. <i>Annals of Neurology</i> , 1998, 44, 980-983.	5.3	137
71	Autopathogenic T Helper Cell Type 1 (Th1) and Protective Th2 Clones Differ in Their Recognition of the Autoantigenic Peptide of Myelin Proteolipid Protein. <i>Journal of Experimental Medicine</i> , 1997, 186, 867-876.	8.5	57
72	Increased immunoreactivity to two overlapping peptides of myelin proteolipid protein in multiple sclerosis. <i>Brain</i> , 1997, 120, 1447-1460.	7.6	71

#	ARTICLE	IF	CITATIONS
73	Encephalitogenicity of murine, but not bovine, DM20 in SJL mice is due to a single amino acid difference in the immunodominant encephalitogenic epitope. <i>Neurochemical Research</i> , 1997, 22, 541-547.	3.3	15
74	Orientation of myelin proteolipid protein in the oligodendrocyte cell membrane. <i>Neurochemical Research</i> , 1996, 21, 431-440.	3.3	15
75	Immunogenic and encephalitogenic epitope clusters of myelin proteolipid protein. <i>Journal of Immunology</i> , 1996, 156, 371-9.	0.8	106
76	Genetic analysis of susceptibility to experimental autoimmune encephalomyelitis in a cross between SJL/J and B10.S mice. <i>Journal of Immunology</i> , 1996, 157, 2186-92.	0.8	77
77	Chapter 29 Expression of myelin proteolipid protein in oligodendrocytes and transfected cells. <i>Progress in Brain Research</i> , 1995, 105, 295-303.	1.4	4
78	An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. <i>Immunity</i> , 1995, 3, 397-405.	14.3	412
79	Minireview: Autoimmune responses to myelin proteolipid protein. <i>Neurochemical Research</i> , 1994, 19, 915-921.	3.3	58
80	Immunolocalization of proteolipid protein peptide 103-116 in myelin. <i>Journal of Neuroscience Research</i> , 1994, 37, 36-43.	2.9	13
81	A single TCR antagonist peptide inhibits experimental allergic encephalomyelitis mediated by a diverse T cell repertoire. <i>Journal of Immunology</i> , 1994, 153, 3326-36.	0.8	150
82	Cytokines and adhesion molecules contribute to the ability of myelin proteolipid protein-specific T cell clones to mediate experimental allergic encephalomyelitis. <i>Journal of Immunology</i> , 1993, 151, 4371-82.	0.8	207
83	Identification and characterization of a second encephalitogenic determinant of myelin proteolipid protein (residues 178-191) for SJL mice. <i>Journal of Immunology</i> , 1992, 149, 783-8.	0.8	110
84	Distinctive molecular markers and biological activities in two tumour-specific murine T suppressor factors. <i>Immunology and Cell Biology</i> , 1991, 69, 135-143.	2.3	0
85	Effects of anti-idiotypic vaccine on tumour growth and on production of soluble factors modulating cell-mediated immunity in vitro. <i>Cancer Immunology, Immunotherapy</i> , 1991, 33, 171-176.	4.2	2
86	Comparison of T suppressor factors from tumour-bearing mice and mice immunized with a monoclonal anti-idiotypic antibody. <i>Cancer Immunology, Immunotherapy</i> , 1990, 31, 151-156.	4.2	5
87	Auto-anti-idiotypic antibodies in mice hyperimmunized with a chemically induced bladder carcinoma. <i>Immunology and Cell Biology</i> , 1988, 66, 167-173.	2.3	2
88	HLA and amyotrophic lateral sclerosis: a systematic review and meta-analysis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 0, , 1-9.	1.7	2